The FDA announced today that it is permitting the restricted use of Zelnorm (tegaserod maleate) under a treatment investigational new drug (IND) protocol to treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) in women younger than 55 who meet strict criteria and have no known or pre-existing heart problems and are in critical need of this drug.
Sometimes when no comparable or satisfactory alternative drug or therapy is available, the FDA will allow...
In Honor of Osteoporosis Awareness and Prevention month we'd like to talk about bone loss in children with Dr. Catherine Gordon. Dr. Gordon...
Read more »
Constipation is a decrease in the frequency of stool (the body's waste product) or difficulty in the formation or passage of stool.Constipation is...
Read more »
Idiopathic means of unknown origin, occurring spontaneously and not traceable to a direct cause. When discussing Migraine disease and other...
Read more »
Idiopathic hypercalciuria is the presence of excess calcium in the urine without obvious cause. This condition can lead to kidney stones or...
Read more »
Idiopathic hypersomnia is sleeping too much (hypersomnia) without an obvious cause. It is different from narcolepsy, because idiopathic hypersomnia...
Read more »
The FDA announced today that it is permitting the restricted use of Zelnorm (tegaserod maleate) under a treatment investigational new drug (IND) protocol to treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) in women younger than 55 who meet strict criteria and have no known or pre-existing heart problems and are in critical need of this drug.
